Molecular Diagnosis of Fluoroquinolone Resistance in *Mycobacterium tuberculosis*

Christine Bernard, Nicolas Veziris, Florence Brossier, Wladimir Sougakoff, Vincent Jarlier, Jérôme Robert, Alexandra Aubry

Sorbonne Universités, UPMC Université Paris 06, CR7, Centre d'Immunologie et des Maladies Infectieuses, CIMI, Team E13 (Bacteriology), Paris, France; INSERM, U1135, Centre d’Immunologie et des Maladies Infectieuses, CIMI, Team E13 (Bacteriology), Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Bactériologie-Hygiène, Paris, France.

As a consequence of the use of fluoroquinolones (FQ), resistance to FQ has emerged, leading to cases of nearly untreatable and extensively drug-resistant tuberculosis. Mutations in DNA gyrase represent the main mechanism of FQ resistance. A full understanding of the pattern of mutations found in FQ-resistant (FQr) clinical isolates, and of their proportions, is crucial for improving molecular methods for the detection of FQ resistance in *Mycobacterium tuberculosis*. In this study, we reviewed the detection of FQ resistance in isolates addressed to the French National Reference Center for Mycobacteria from 2007 to 2012, with the aim of evaluating the performance of PCR sequencing in a real-life context. *gyrA* and *gyrB* sequencing, performed prospectively on *M. tuberculosis* clinical isolates, was compared for FQ susceptibility to 2 mg/liter ofloxacin by the reference proportion method. A total of 605 isolates, of which 50% were multidrug resistant, were analyzed. The in FQ r strains among multidrug-resistant (MDR) strains during the time of the study was alarming (8% to 30%). The majority (78%) of the isolates with *gyrA* mutations were FQr, whereas only 36% of those with *gyrB* mutations were FQr. Only 12% of the FQr isolates had a single mutation in *gyrB*. Combined *gyrA* and *gyrB* sequencing led to >93% sensitivity for detecting resistance. The analysis of the four false-positive and the five false-negative results of *gyrA* and *gyrB* sequencing illustrated the actual limitations of the reference proportion method. Our data emphasize the need for combined *gyrA* and *gyrB* sequencing in the investigation of FQ susceptibility in *M. tuberculosis* and challenge the validity of the current phenotype-based approach as the diagnostic gold standard for determining FQ resistance.

Tuberculosis (TB) remains one of the most serious infectious diseases worldwide, causing 1.8 million deaths each year (1). The emergence and transmission of drug-resistant *Mycobacterium tuberculosis* strains further threaten TB control efforts. The treatment of infection due to multidrug-resistant (MDR) *M. tuberculosis* (MDR-TB) (i.e., that which is resistant to isoniazid and rifampin) requires the use of fluoroquinolones (FQ), since it is correlated with good prognosis (2). Unfortunately, the extensive use of FQ has led to the emergence of extensively drug-resistant (XDR) isolates, defined as MDR with resistance to any FQ and at least one of the three injectable second-line drugs (amikacin, kanamycin, or capreomycin). Disease caused by XDR *M. tuberculosis* is associated with very poor treatment outcomes close to the historical outcomes, when no chemotherapy for TB was available (3).

FQ are antibiotics with broad-spectrum antimicrobial activities and are therefore widely used for the treatment of bacterial infections of the respiratory, gastrointestinal, and urinary tracts, as well as of sexually transmitted diseases and chronic osteomyelitis (4). The FQ resistance rates in TB patients have been estimated to lie between 0.15 and 30%, depending on the country (5–8). The rates are higher among patients exposed to FQ prior to the diagnosis of TB, i.e., in cases of “acquired” resistance (6). However, in some countries, especially where FQ consumption is very high, FQ resistance is often due to the transmission of strains that are already FQ resistant (FQr) (7, 8).

FQ resistance is defined by the WHO as resistance to 2 mg/liter ofloxacin (OFX) (9). The conventional methods for drug susceptibility testing (DST) involve the primary culture of specimens and isolation of *M. tuberculosis*. This process has a long turnaround time of several weeks. Over the past several years, molecular techniques have been developed for the rapid detection of resistance to antituberculous agents (10). DNA gyrase, the only target of FQ in *M. tuberculosis*, is a GyrA2GyrB2 tetrameric enzyme containing two A and two B subunits encoded by the *gyrA* and *gyrB* genes, respectively. Mutations within the highly conserved region, the so-called quinolone resistance-determining region (QRDR) of *gyrA* and/or *gyrB*, have been reported to be responsible for ≥70% of FQ resistance in *M. tuberculosis*, affecting most commonly the GyrA subunit and less frequently the GyrB subunit as well (11). The vast majority of the published studies are retrospective, and thus, the molecular diagnoses in these studies were made for strains already known to be fluoroquinolone resistant or susceptible. To test the potential of molecular diagnosis in a real-life context, we conducted a 6-year prospective study using combined *gyrA* and *gyrB* sequencing for an initial evaluation of fluoroquinolone susceptibility.

**MATERIALS AND METHODS**

**Bacterial strains and selection of isolates.** This prospective study included all isolates for which a genotypic and phenotypic diagnosis of FQ resistance was established between 2007 and 2012 at the French National Reference Center for Mycobacterial Infections.

**Received** 8 August 2014  **Returned for modification** 13 November 2014  **Accepted** 17 December 2014  **Address for correspondence** Alexandra Aubry, alexandra.aubry@upmc.fr  **Copyright © 2015, American Society for Microbiology. All Rights Reserved.**  doi:10.1128/AAC.04058-14
GyrB S470, D473, P478, S486, D500, A506, E540, A543, A547, G551, and G559 in the most frequently used numbering system (CAB02426.1) correspond to GyrB S431, D434, D437, A438, E470, A473, P478, S476, D500, A506, E540, A543, A547, G551, and G559 in the most frequently used numbering system (11,14). The correspondences with the proposed numbering system (11) are given in Tables 1 and 2 (11). The implication of DNA gyrase substitutions in FQ resistance noted in the tables corresponds to the numbers of isolates studied rose every year, from 71 in 2007 to 137 in 2012, but the proportion of MDR isolates remained the same (ca. 50%) (Table 3). Most of the isolates

**TABLE 1** Multiple substitutions in GyrA and/or GyrB found in fluoroquinolone-resistant and -susceptible clinical *M. tuberculosis* isolates

<table>
<thead>
<tr>
<th>Substitutions by type</th>
<th>No. of isolates:</th>
<th>FQ-R (n = 6)</th>
<th>FQ-S (n = 2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GyrA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T80A/A90E</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T80A/A90G</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A90V/D94G</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A90V/D94H</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A90V/D94N</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A90V/D94F</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GyrA + GyrB</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D94G/A543V</td>
<td>1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*GyrB A543V corresponds to GyrB A504V in the proposed numbering system (11).*

Reference Center for Mycobacteria (NRC). These isolates comprised (i) all MDR strains isolated in France, (ii) some isolates that had been sent to the NRC because of high suspicion of being MDR (and that had been tested for second-line drug susceptibility immediately after isolation but that eventually turned out to be resistant to isoniazid or rifampin only, or even susceptible to both drugs), and (iii) some non-MDR isolates from patients for whom treatment with FQ was considered because of intolerance of or resistance to antituberculous drugs.

**Drug susceptibility testing.** *In vitro* DST was performed on Lowenstein-Jensen (LJ) medium according to the proportion method (12) with rifampin (40 mg/liter), isoniazid (0.2 and 1 mg/liter), OFX (2 mg/liter), amikacin and capreomycin (40 mg/liter each), and kanamycin (30 mg/liter), and a critical proportion of 1% (9).

A loopful of culture was suspended in water (500 μl) and heated at 95°C for 15 min. The DNA used for PCR amplification was obtained by heat shock extraction (1 min at 95°C and 1 min on ice, repeated five times). A volume of 5 μl was used in the PCRs with the oligonucleotide primers described below. For FQ resistance, the QRDRs of *gyrA* and *gyrB* were amplified and sequenced using primers PRI8 (5'-YGGTGGRCTRTTRC CYGGCGA-3') and PRI9 (5'-CGCGCGGTGTATGCRATG-3') for *gyrA* and primers gyrBa (5'-GAGTTGGTCCGCGTAAAGGC-3') and gyrBe (5'-CGGCCATCAAGCAGATCTTG-3') for *gyrB* (13).

After amplification, unincorporated nucleotides and primers were removed by filtration with Microcon 100 microconcentrators (Amicon, Inc., Beverly, MA), and the amplicons were sequenced using the BigDye Terminator version 3.1 cycle sequencing kit (Life Technologies), according to the manufacturer’s instructions.

The amino acid substitution S95T in *gyrA* was omitted from the summary tables because it corresponds to a well-known polymorphism that does not confer drug resistance (11).

When more than one substitution was observed in one strain (double or triple substitution), we noted two scenarios: (i) one of the substitutions was observed as a single substitution elsewhere, or (ii) the substitutions were never observed independently of one another. In both scenarios, the substitutions were listed as single and multiple substitutions. The mutations that were never observed independently of one another are noted in the tables. All substitutions in *gyrA* and *gyrB* were annotated according to the numbering system of *M. tuberculosis*, in which the QRDR of *M. tuberculosis* GyrA ranges from codon 74 to codon 113, and the QRDR of GyrB ranges from codon 500 to codon 540 (this is the most frequently GyrB numbering system used in the literature [GenBank accession no. CAB02426.1]) (11,14). The correspondences with the proposed numbering system are given as footnotes in Tables 1 and 2 (11). The implication of DNA gyrase substitutions in FQ resistance noted in the tables corresponds to the results of biochemical studies found in the literature, whose references are noted in the tables.

**Statistical tests.** Chi-square tests were performed using the BiostatTGV website (http://marne.u707.jussieu.fr/biostatgv/). The results were considered significant at a P value of <0.05.

**RESULTS**

**Drug susceptibility pattern of the isolates included in this study.** A total of 605 *M. tuberculosis* isolates obtained from clinical specimens were sent to the NRC during 2007 to 2012 for the diagnosis of FQ resistance. The number of isolates studied rose every year, from 71 in 2007 to 137 in 2012, but the proportion of MDR isolates remained the same (ca. 50%) (Table 3). Most of the isolates

**TABLE 2** Substitutions in GyrB found in fluoroquinolone-resistant and -susceptible clinical *M. tuberculosis* isolates

<table>
<thead>
<tr>
<th>Substitution in GyrB</th>
<th>No. of isolates by resistance type</th>
<th>FQ-R</th>
<th>FQ-S</th>
<th>% of total substitutions in GyrB</th>
<th>Implication in FQ resistance in <em>M. tuberculosis</em> demonstrated in the literature (reference[s])</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>MDR</td>
<td>Non-MDR</td>
<td>MDR</td>
<td>Non-MDR</td>
</tr>
<tr>
<td>S470I</td>
<td></td>
<td>1</td>
<td></td>
<td>4.5</td>
<td></td>
</tr>
<tr>
<td>D473N</td>
<td></td>
<td>1</td>
<td></td>
<td>4.5</td>
<td></td>
</tr>
<tr>
<td>P478A</td>
<td></td>
<td>1</td>
<td></td>
<td>9.0</td>
<td></td>
</tr>
<tr>
<td>S486F</td>
<td></td>
<td>2</td>
<td></td>
<td>4.5</td>
<td></td>
</tr>
<tr>
<td>S486Y</td>
<td></td>
<td>9.0</td>
<td></td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>D500A</td>
<td></td>
<td>1</td>
<td></td>
<td>4.5</td>
<td></td>
</tr>
<tr>
<td>D500N</td>
<td></td>
<td>1</td>
<td></td>
<td>4.5</td>
<td></td>
</tr>
<tr>
<td>A506G</td>
<td></td>
<td>1</td>
<td></td>
<td>4.5</td>
<td></td>
</tr>
<tr>
<td>E540V</td>
<td></td>
<td>3</td>
<td></td>
<td>18.5</td>
<td></td>
</tr>
<tr>
<td>A543V</td>
<td></td>
<td>2</td>
<td></td>
<td>9.0</td>
<td></td>
</tr>
<tr>
<td>A547V</td>
<td></td>
<td>1</td>
<td></td>
<td>4.5</td>
<td></td>
</tr>
<tr>
<td>G551R</td>
<td></td>
<td>1</td>
<td></td>
<td>4.5</td>
<td></td>
</tr>
<tr>
<td>G559A</td>
<td></td>
<td>4</td>
<td></td>
<td>18.5</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td>8</td>
<td></td>
<td>6</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> GyrB S470, D473, P478, S486, D500, A506, E540, A543, A547, G551, and G559 in the most frequently used numbering system (CAB02426.1) correspond to GyrB S431, D434, D437, A438, E470, A473, P478, S476, D500, A506, E540, A504, A508, G512, and G520 in the proposed numbering system (11), respectively.

<sup>b</sup> ND, not demonstrated.
(78%) were resistant to isoniazid or rifampin or both: 297 (49%) were resistant to both isoniazid and rifampin (i.e., MDR or XDR), and 176 (29%) were resistant either to rifampin (n = 25) or isoniazid (n = 151). Phenotypic OFX resistance was found in 70 (12%) of the 605 isolates. Among the OFX-resistant (OFX\textsuperscript{r}) isolates, 51 (66/70 [94%]) were MDR, while one was resistant to isoniazid but susceptible to rifampin, and two were susceptible to both isoniazid and rifampin. The amino acid substitutions were located at 11 positions. No substitution was significantly more frequent than any other; there were four G559A, four E540V, three S486F/Y, two P478A, two D500A/N, and two A543V substitutions, and one each of the S470I, D473N, A506G, A547V, and G551R substitutions (Table 2).

### TABLE 3

<table>
<thead>
<tr>
<th>Resistance profile\textsuperscript{d}</th>
<th>No. of isolates (no. of FQ-R isolates) in:</th>
<th>Total no. of isolates (no. of FQ-R isolates)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2007</td>
<td>2008</td>
</tr>
<tr>
<td>INH-S + RIF-S</td>
<td>19 (0)</td>
<td>20 (0)</td>
</tr>
<tr>
<td>INH-R, non-MDR</td>
<td>15 (0)</td>
<td>16 (0)</td>
</tr>
<tr>
<td>RIF-R, non-MDR</td>
<td>1 (0)</td>
<td>6 (1)</td>
</tr>
<tr>
<td>MDR</td>
<td>36 (3)</td>
<td>48 (6)</td>
</tr>
<tr>
<td>XDR</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Total</td>
<td>71</td>
<td>90</td>
</tr>
</tbody>
</table>

\textsuperscript{d} INH, isoniazid; RIF, rifampin; S, susceptible; R, resistant; MDR, multidrug resistant; XDR, extensively drug resistant (all XDR strains are included within the MDR strains).

### TABLE 4

<table>
<thead>
<tr>
<th>Substitution in GyrA</th>
<th>FQ-R</th>
<th>FQ-S</th>
<th>% of total substitutions in GyrA</th>
<th>Implication in FQ resistance in M. tuberculosis demonstrated in the literature (reference[s])</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MDR</td>
<td>Non-MDR</td>
<td>MDR</td>
<td>Non-MDR</td>
</tr>
<tr>
<td>T80A</td>
<td>1\textsuperscript{b}</td>
<td>7 + 1\textsuperscript{b}</td>
<td>6 + 1\textsuperscript{b}</td>
<td>19.9</td>
</tr>
<tr>
<td>G88C</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1.2</td>
</tr>
<tr>
<td>A90E\textsuperscript{d}</td>
<td>1</td>
<td>1</td>
<td>2.4</td>
<td>ND\textsuperscript{e}</td>
</tr>
<tr>
<td>A90G\textsuperscript{d}</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2.4</td>
</tr>
<tr>
<td>A90V</td>
<td>14 + 4\textsuperscript{d}</td>
<td>2</td>
<td>22.2</td>
<td>Yes (33)</td>
</tr>
<tr>
<td>S91P</td>
<td>5</td>
<td>5</td>
<td>6.2</td>
<td>Yes\textsuperscript{a}</td>
</tr>
<tr>
<td>D94A</td>
<td>13</td>
<td>13</td>
<td>16.1</td>
<td>Yes (33)</td>
</tr>
<tr>
<td>D94G</td>
<td>10 + 1\textsuperscript{b}</td>
<td>2</td>
<td>16.1</td>
<td>Yes (33)</td>
</tr>
<tr>
<td>D94H</td>
<td>3 + 1\textsuperscript{b}</td>
<td>1</td>
<td>4.9</td>
<td>Yes (33)</td>
</tr>
<tr>
<td>D94N</td>
<td>2 + 1\textsuperscript{b}</td>
<td>1</td>
<td>4.9</td>
<td>Yes (33)</td>
</tr>
<tr>
<td>D94Y</td>
<td>2 + 1\textsuperscript{b}</td>
<td>1</td>
<td>3.7</td>
<td>Yes (33)</td>
</tr>
<tr>
<td>Q101E</td>
<td>1</td>
<td>1</td>
<td>1.2</td>
<td>ND</td>
</tr>
<tr>
<td>Total</td>
<td>60</td>
<td>3</td>
<td>9</td>
<td>100</td>
</tr>
</tbody>
</table>

\textsuperscript{a} Seven isolates harbored 2 substitutions.

\textsuperscript{b} Isolate harboring two substitutions.

\textsuperscript{c} ND, not demonstrated.

\textsuperscript{d} Substitution systematically associated with other GyrA substitutions (see Table 1 for details).

\textsuperscript{e} Considered to be implicated in FQ resistance despite the absence of unequivocal demonstration, since it is frequently observed in FQ-R strains (11) and is included in the MTBDR\textsubscript{sl} line probe assay.
As opposed to what was observed for GyrA, no isolate harbored more than one substitution in GyrB. However, one isolate showed a substitution in both GyrA (D94A) and GyrB (A543V) (Table 1).

**Distribution of DNA gyrase mutations regarding the susceptibility to FQ.** Among the isolates included in this study, 535 were OFX susceptible (OFX*) and 70 were OFX (Table 3). The distributions of substitutions in GyrA and GyrB according to the FQ sensitivities of the isolates are detailed in Tables 2 and 4. Among the 74 isolates with a substitution(s) in GyrA, 16 (harboring 18 substitutions) were OFX*, whereas the majority were OFX* (n = 58 [78%], harboring 63 substitutions). Among the 22 isolates with substitutions in GyrB, more isolates were OFX* (n = 14 [64%], harboring 14 substitutions) than OFX* (n = 8 [36%], harboring eight substitutions). Among the OFX isolates, one isolate harbored a substitution in both GyrA (D94A) and GyrB (A543V). The proportion of substitutions in GyrB associated with FQ resistance was significantly lower than that in GyrA (36% versus 78%, P = 0.0002).

Surprisingly, no substitution in GyrA or GyrB was found in five of the 70 (7%) OFX isolates, which were mainly MDR isolates (n = 4). For these isolates, the proportion of colonies growing on OFX-containing LJ medium was close to the breakpoint given by the proportion method for four isolates (1%, 1%, 2%, and 5% mutants) and higher for one isolate (proportion of colonies growing on OFX-containing LJ medium, 25%). The sequencing of gyrA and gyrB was therefore also performed on these colonies growing on OFX-containing LJ medium, and substitutions were found in four isolates, with GyrA D94G/Y substitutions in three isolates and a GyrB N538K substitution in one isolate. No substitutions in GyrA or GyrB were found in the remaining isolate, although it harbored the highest proportion of colonies growing on OFX-containing LJ medium (25%).

On the other hand, 30 OFX isolates harbored 18 substitutions in GyrA and/or 14 substitutions in GyrB. Among these 30 strains, two strains harbored substitutions known to be implicated in FQ resistance (GyrB D500A and GyrB E540V) (14, 15), and another two strains harbored substitutions whose implications in FQ resistance are not known (GyrA Q101E and GyrB S470I) (Tables 2 and 4).

Substitutions implicated in FQ resistance were more frequent in MDR than in non-MDR isolates (42 versus 2%, P < 0.01).

**DISCUSSION**

Knowing the epidemiology of DNA gyrase mutations is of primary importance for the design of a reliable approach for diagnosing FQ resistance. The previously published studies in this field of investigation have some limitations: (i) most studies evaluated the performance of molecular diagnosis for FQr isolates only (11, 16–18), (ii) most studies were performed on retrospectively chosen isolates with a high prevalence of FQ resistance (most were >50%) (11), and (iii) only half of the studies included sequencing of gyrA/gyrB (11, 16–30). To our knowledge, the present study is the largest study published that was performed prospectively, apart from that by Hu et al. (28), which was performed prospectively and included fewer isolates selected from a population in which the prevalence of FQ resistance was similar to that studied here (14 versus 12%).

The first important finding of our study was the increase in the proportion of FQ* isolates among the MDR-TB isolates, from 8% in 2007 to 30% in 2012 (P = 0.07). This increase is due to the marked increase in the number of MDR-TB cases observed in France in the last years in patients born in the former Soviet Union (6 cases in 2007, 10 in 2008 and 2009, 11 in 2010, 21 in 2011, and 47 in 2012) (31). Incidentally, a recent study performed in the Russian Federation reported an FQ resistance rate as high as 62% in consecutive MDR-TB cases (26). This major increase is a challenge to the existing health care facilities in the management of MDR-TB and XDR-TB.

The second major result of our study is that FQ* isolates harbored more substitutions in GyrA or GyrB than is generally reported in the literature (93% versus an average of 81% in the 13 studies providing both gyrA and gyrB sequence data; P = 0.02) (Tables 2 and 4) (11, 16–30). Among these substitutions found in the FQ isolates, we observed a higher proportion in GyrB than was previously published (11.5% versus an average of 3%) (11). In our study, substitutions in GyrB at position E540 were the most frequently found, followed by S486Y and A543V and D500N (Table 2). The overall geographical distribution of the substitutions in GyrB has been reported to be highly variable (11). The reason for this variability remains unclear. It could be speculated that these substitutions that are most likely phenotypically silent simply occur more frequently in certain geographical regions. The variability might also be due to selection bias, since the vast majority of studies were made retrospectively. Regarding the substitutions in GyrA, those at position D94 were the most frequent, followed by A90V and S91P (Table 4), as previously reported (11, 16–30).

We analyzed the performance of the DNA sequencing strategy for detecting FQ resistance compared to that of the proportion method, using OFX (2 mg/liter), which is considered the reference method. We took into account epidemiological and biochemical studies on the implication of DNA gyrase substitutions in FQ resistance (14, 15, 32–35) (Tables 2 and 4). In our population, in which the prevalence of FQ resistance was 12%, the sensitivity, specificity, and positive and negative predictive values were the 92.9%, 99.2%, 94.2%, and 99.1%, respectively. The sensitivity and specificity were similar to those previously published (11, 15–29).

Analyzing our results closely, i.e., the four false-positive and the five false-negative results, we see a very complex picture in which the sole presence or absence of mutations does not allow a prediction of susceptibility or resistance, and it challenges the current phenotype-based approach as the gold standard for FQ resistance detection while the potential of molecular methods is still under evaluation (36, 37). Indeed, among the 4 false-positive results, two strains harbored substitutions in GyrB (D500A and E540V) known to be implicated in low-level FQ resistance, and two strains harbored substitutions whose implication in FQ resistance is not known (GyrA Q101E and GyrB S470I). Among the 5 false-negative results, all strains harbored a percentage of mutants of ≤25%, and the sequencing of colonies growing on OFX-containing LJ medium revealed the presence of substitutions well known to be implicated in FQ resistance for 4 strains (GyrA D94G/Y and GyrB N538K).

The questionable ability of existing phenotypic and PCR sequencing DST to properly classify strains as susceptible or resistant was also raised for other antitubercular agents. For example, regarding rifampin, some rpoB mutations entailing low-level resistance that is not detected by conventional phenotypic DST have a negative impact on treatment efficacy (36, 38).

Finally, it is of crucial importance to determine whether low-level resistance not detected by phenotypic methods has an impact...
on treatment efficacy and whether the phenotypic and/or molecular DST methods might be able to detect these resistance levels. The answer to both questions seems to be yes, considering (i) in vitro studies showing that the MICs of moxifloxacin or gatifloxacin, the most active fluoroquinolones against *M. tuberculosis*, may be lower than their peak serum levels for some ofloxacin-resistant strains of *M. tuberculosis* (14–16, 20–22, 37), (ii) a murine model whose results support current WHO recommendations to use moxifloxacin when there is resistance to early generation fluoroquinolones, such as ofloxacin, when moxifloxacin MICs of ≤2 mg/liter (39, 40), and (iii) recent clinical data regarding the excellent outcome of the Bangladesh regimen used to treat XDR-TB patients, including among patients with low-level gatifloxacin resistance, whereas the relapses and death were observed among patients with high-level gatifloxacin resistance (41).

ACKNOWLEDGMENTS

The French National Reference Center for Mycobacteria is supported by an annual grant of the Institut National de Veille Sanitaire. The research was supported by the Fondation du Souffle and the Fonds de Dotation Centre for Mycobacteria.

REFERENCES


A, Suzuki Y. 2013. Characterization of extensively drug-resistant Myco-
doi.org/10.1016/j.tube.2012.10.007.
and genetic characterization of second-line drug-resistant and exten-
sively drug-resistant Mycobacterium tuberculosis in rural China. Antimi-
.00102-13.
and accurate diagnosis of extensively drug-resistant tuberculosis: report
from a tertiary care center in India. J Clin Microbiol 49:1588–1590. http:
//dx.doi.org/10.1128/JCM.00113-11.
2011. Incidence of moxifloxacin resistance in clinical Mycobacterium tu-
//dx.doi.org/10.1128/JCM.00231-11.
31. Bernard C, Brossier F, Sougakoff W, Veziris N, Frechet-Jachym M,
Metivier N, Renvoisé A, Robert J, Jarlier V; MDR-TB Management
Group of the NRC. 2013. A surge of MDR and XDR tuberculosis in
France among patients born in the Former Soviet Union. Euro Surveill
Id=102-13.
into fluoroquinolone resistance in Mycobacterium tuberculosis: functional
doi.org/10.1371/journal.pone.0039754.
2006. Novel gyrA mutations in quinolone-resistant and -hypersuscepti-
ble clinical isolates of Mycobacterium tuberculosis: functional analysis
34. Matrat S, Veziris N, Mayer C, Jarlier V, Truffot-Pernot C, Camuset J,
Bouvet E, Cambau E, Aubry A. 2006. Functional analysis of DNA gyrase
mutant enzymes carrying mutations at position 88 in the A subunit found
in clinical strains of Mycobacterium tuberculosis resistant to fluoroquino-
/10.1128/AAC.00944-06.
35. Pantel A, Petrella S, Matrat S, Brossier F, Bastian S, Reitter D, Jarlier V,
Mayer C, Aubry A. 2011. DNA gyrase inhibition assays are necessary to
demonstrate fluoroquinolone resistance secondary to gyrB mutations in
36. Van Deun A, Aung KJM, Bola V, Lebeke R, Hossain MA, de Rijk WB,
resistance tests for tuberculosis: challenging the gold standard. J Clin Mi-
37. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD,
Bottger EC. 2012. gyrA mutations and phenotypic susceptibility levels to
ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tubercu-
/jac/dks033.
38. Rigouts L, Gumusboga M, de Rijk WB, Nduwamahoro E, Uwizeye C,
de Jong B, Van Deun A. 2013. Rifampin resistance missed in automated
liquid culture system for Mycobacterium tuberculosis isolates with specific
.1128/JCM.00948-10.
Farinotti R, Veziris N. 2010. Should moxifloxacin be used for the treat-
ment of extensively drug-resistant tuberculosis? An answer from a murine
Impact of fluoroquinolone resistance on bactericidal and sterilizing activ-
ity of a moxifloxacin-containing regimen in murine tuberculosis. Antimi-
.00506-13.
41. Aung KJ, Van Deun A, Declercq E, Sarkar MB, Das PK, Hossain MA,
Rieder HL. 2014. Successful ‘9-month Bangladesh regimen’ for multi-
drug-resistant tuberculosis among over 500 consecutive patients. Int J